- Home
- REAL vs ZURA Comparison
REAL vs ZURA Comparison
Compare REAL & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REAL | ZURA |
|---|---|---|
| Founded | 2011 | 2022 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 521.8M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | REAL | ZURA |
|---|---|---|
| Price | $9.11 | $6.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $17.00 | $11.78 |
| AVG Volume (30 Days) | ★ 3.0M | 502.2K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.55 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $692,845,000.00 | N/A |
| Revenue This Year | $14.30 | N/A |
| Revenue Next Year | $10.19 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.38 | N/A |
| 52 Week Low | $4.61 | $0.99 |
| 52 Week High | $17.39 | $7.25 |
Technical Indicators
Market Signals| Indicator | REAL | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 41.40 | 48.93 |
| Support Level | $7.21 | $5.49 |
| Resistance Level | $11.17 | $6.99 |
| Average True Range (ATR) | 0.52 | 0.48 |
| MACD | 0.11 | -0.01 |
| Stochastic Oscillator | 49.08 | 57.97 |
Price Performance
Historical ComparisonAbout REAL The RealReal Inc.
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.